Second-generation anti-VEGF agents, like aflibercept 8 mg and faricimab, show improved efficacy and treatment durability in ...
David Eichenbaum, MD, FASRS, recalls an early-career case managing bilateral diabetic macular edema with frequent ...
Celltrion, Inc. announced that the US Food and Drug Administration (FDA) has approved Eydenzelt (aflibercept-boav), biosimilar referencing Eylea (aflibercept), for the treatment of neovascular (wet) ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today results from two Phase III studies evaluating the efficacy and safety ...
WATERTOWN, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of ...
Kiora Pharmaceuticals, Inc. (($KPRX)) announced an update on their ongoing clinical study. Study Overview: Kiora Pharmaceuticals, Inc. is ...
Two mechanisms of retinal impairment based on papilledema severity were identified among patients with idiopathic intracranial hypertension.
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) shared details on Tuesday about its pivotal Phase 3 program of Duravyu (vorolanib intravitreal insert) for diabetic macular edema (DME) and began first ...
– DURAVYU now in Phase 3 for the two largest, multi-billion-dollar retinal disease markets, wet AMD and DME with first patient dosing in pivotal Phase 3 DME trials anticipated in Q1 2026 – – New ...
Kyowa Kirin Co (($KYKOF)) announced an update on their ongoing clinical study. Kyowa Kirin Co. is conducting a Phase 2 clinical study titled ‘A ...
Regeneron has settled its patent dispute with Celltrion, giving the go-ahead for another biosimilar to its blockbuster eye drug Eylea (aflibercept) to hit the U.S. market in just over a year. The deal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback